fy year-seven financial guidance unchanged.
qtr-four earnings per share was $num-two; qtr-four adjusted earnings per share was $num-one.
qtrly tavr sales of $num-one million, up num-three%.
tavr sales negatively impacted in last several weeks of qtr-four due to impact omicron had on hospital resources in u.s.
co is reaffirming year-seven sales guidance for all product groups.
sees qtr-one total sales between $num-one and $num-two billion, and qtr-one adjusted earnings per share of $num-three to $num-four.
believe that opportunity to serve our patients will nearly double between now and num-two.